Skip to main content

Table 4 In your experience, can the use of biologics in JDM patients reduce any of the following complications?

From: Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America

Calcinosis 21/40 52.5%
Muscle atrophy 11/40 27.5%
Lipodystrophy 7/40 17.5%
Osteonecrosis 8/40 20%
Ulcerative disease 17/40 42.5%
Internal organ damage/perforation/necrosis 10/40 25%
Other complications 19/40 47.5%